免疫治疗初级心脏软组织肉瘤患者的临床结果:多中心回顾性研究
Amin H Nassar1, Edward El-Am2, Ryan Denu3
1Yale University School of Medicine, New Haven, Connecticut, USA.
JACC. CardioOncology
|March 21, 2024
概括
免疫检查点抑制剂 (ICI) 在初级心脏软组织肉瘤 (CSTS) 中表现出有限的疗效,反应率低. 然而,非血管肉瘤CSTS患者的一个子组经历了持久的好处,尽管毒性增加.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 心血管研究研究心血管研究
背景情况:
- 初级心脏软组织肉瘤 (CSTS) 是一种罕见且具有攻击性的瘤,主要影响年轻人.
- 从历史上看,CSTS患者的治疗结果很差,这凸显了对新型治疗策略的需求.
研究的目的:
- 评估免疫检查点抑制剂 (ICI) 在被诊断为CSTS的患者的临床疗效和安全性.
- 确定ICI对该患者群体的整体生存期 (OS) 和无进展生存期 (PFS) 的影响.
主要方法:
- 一项回顾性多机构队列研究分析了2015年至2022年期间以ICI为基础的疗法治疗的CSTS患者.
- 卡普兰-梅尔分析被用来估计OS和PFS. 响应评估遵循RECIST v1.1标准,不良事件使用CTCAE v5.0.0进行分级.
主要成果:
- 在18名具有晚期/转移性CSTS的可评估患者中,ICI的客观应答率为11.1%.
- 晚期/转移性CSTS的PFS和OS中位数分别为5.7个月和14.9个月.
- 与血管瘤患者相比,非血管瘤CSTS患者的PFS (11个月与1.7个月) 和OS (24个月与3.0个月) 显著较长. 主要在非血管肉瘤组中注意到毒性.
结论:
- 免疫检查点抑制剂 (ICI) 在初级心脏软组织肉瘤 (CSTS) 中表现出适度的活性.
- 一部分非血管肉瘤CSTS患者可能会对ICI产生持久的反应,尽管这与毒性增加有关.
- 进一步的研究是有必要的,以优化ICI治疗CSTS,特别是血管肉瘤亚型.
相关概念视频
02:56Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K